SDHB: Difference between revisions

Jump to navigation Jump to search
Newer edit →
VisualWikitext
WikiBot (talk | contribs)
Bots, Bureaucrats, bureaucrats, interwiki, nocaptcha, Administrators
57,550 edits
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)
 
m Bot: HTTP→HTTPS (v475)
Line 1: Line 1:
{{protein
{{Infobox_gene}}
| Name = succinate dehydrogenase complex, subunit B, iron sulfur (Ip)
| caption =
| image =
| width =
| HGNCid = 10681
| Symbol = SDHB
| AltSymbols = SDH1, SDH
| EntrezGene = 6390
| OMIM = 185470
| RefSeq = NM_003000
| UniProt = P21912
| PDB =
| ECnumber = 1.3.99.1
| Chromosome = 1
| Arm = p
| Band = 36.1
| LocusSupplementaryData = -p35
}}
{{SI}}


'''Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial''' (SDHB) also known as '''iron-sulfur subunit of complex II''' (Ip) is a [[protein]] that in humans is encoded by the ''SDHB'' [[gene]].<ref name="entrez">{{cite web | title = Entrez Gene: succinate dehydrogenase complex| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6390| accessdate = }}</ref><ref name="pmid2302193">{{cite journal |vauthors=Kita K, Oya H, Gennis RB, Ackrell BA, Kasahara M | title = Human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of iron sulfur (Ip) subunit of liver mitochondria | journal = Biochem. Biophys. Res. Commun. | volume = 166 | issue = 1 | pages = 101–8 |date=January 1990 | pmid = 2302193 | doi = 10.1016/0006-291X(90)91916-G| url = | issn = }}</ref><ref name="pmid7622059">{{cite journal |vauthors=Au HC, Ream-Robinson D, Bellew LA, Broomfield PL, Saghbini M, Scheffler IE | title = Structural organization of the gene encoding the human iron-sulfur subunit of succinate dehydrogenase | journal = Gene | volume = 159 | issue = 2 | pages = 249–53 |date=July 1995 | pmid = 7622059 | doi = 10.1016/0378-1119(95)00162-Y| url = | issn = }}</ref>


==Overview==
The [[succinate dehydrogenase]] (also called SDH or Complex II) protein complex [[Catalysis|catalyzes]]  the oxidation of succinate (succinate + ubiquinone => fumarate + ubiquinol). SDHB is one of four protein subunits forming succinate dehydrogenase, the other three being [[SDHA]], [[succinate dehydrogenase complex subunit C|SDHC]] and [[SDHD]]. The SDHB subunit is connected to the [[SDHA]] subunit on the hydrophilic, catalytic end of the SDH complex. It is also connected to the [[succinate dehydrogenase complex subunit C|SDHC]]/[[SDHD]] subunits on the hydrophobic end of the complex anchored in the mitochondrial membrane. The subunit is an [[iron-sulfur protein]] with three iron-sulfur clusters. It weighs 30 [[Atomic mass unit|kDa]].
'''SDHB''' is an acronym for '''succinate dehydrogenase complex subunit B'''.


The term SDHB can refer to:
==Structure==
The gene that codes for the SDHB protein is [[Nuclear DNA|nuclear]], not [[Mitochondrial DNA|mitchondrial DNA]]. However, the expressed protein is located in the inner membrane of the [[mitochondria]]. The location of the gene in humans is on the [[Chromosome 1 (human)|first chromosome]] at [[Locus (genetics)|locus]] p36.1-p35. The [[gene]] is coded in 1,162 base pairs, partitioned in 8 [[exon]]s.<ref name = "entrez" /> The expressed protein weighs 18.6 kDa and is composed of 180 amino acids.<ref name=COPaKB>{{cite journal | vauthors = Zong NC, Li H, Li H, Lam MP, Jimenez RC, Kim CS, Deng N, Kim AK, Choi JH, Zelaya I, Liem D, Meyer D, Odeberg J, Fang C, Lu HJ, Xu T, Weiss J, Duan H, Uhlen M, Yates JR, Apweiler R, Ge J, Hermjakob H, Ping P | title = Integration of cardiac proteome biology and medicine by a specialized knowledgebase | journal = Circulation Research | volume = 113 | issue = 9 | pages = 1043–53 | date = Oct 2013 | pmid = 23965338 | pmc = 4076475 | doi = 10.1161/CIRCRESAHA.113.301151 }}</ref><ref name="url_COPaKB">{{cite web | url = http://www.heartproteome.org/copa/ProteinInfo.aspx?QType=Protein%20ID&QValue=P21912 | work = Cardiac Organellar Protein Atlas Knowledgebase (COPaKB) | title = SDHB - Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial }}</ref> SDHB contains the [[iron-sulphur cluster]]s necessary for tunneling electrons through the complex. It is located between [[SDHA]] and the two [[transmembrane]] subunits [[SDHC (gene)|SDHC]] and [[SDHD]].<ref>{{cite journal|last1=Sun|first1=F|last2=Huo|first2=X|last3=Zhai|first3=Y|last4=Wang| first4=A|last5=Xu|first5=J|last6=Su|first6=D|last7=Bartlam|first7=M|last8=Rao|first8=Z|title=Crystal structure of mitochondrial respiratory membrane protein complex II.|journal=Cell|date=1 July 2005|volume=121|issue=7|pages=1043–57|pmid=15989954|doi=10.1016/j.cell.2005.05.025}}</ref>


*  The protein subunit itself.
==Function==
*  The gene that codes for this protein.
[[Image:SDHBfunction.svg|thumb|right|300px|'''Figure 1''': Function of the SDHB protein. Electrons are transferred from the Citric Acid Cycle to the Respiratory Chain. Electron path is shown by red arrows.]]


The [[succinate dehydrogenase]] (SDH) protein complex catalyzes  the oxidation of succinate (succinate + ubiquinone => fumarate + ubiquinol). The SDHB subunit is connected to the [[SDHA]] subunit on the hydrophilic, catalytic end of the SDH complex. It is also connected to the [[SDHC]]/[[SDHD]] subunits on the hydrophobic end of the complex anchored in the mitochondrial membrane. The subunit is an iron-sulfur protein with three iron-sulfur clusters. It weighs 30 [[Atomic mass unit|kDa]].
The SDH complex is located on the inner membrane of the [[mitochondria]] and participates in both the [[Citric Acid Cycle]] and [[Respiratory chain]]. SDHB acts as an intermediate in the basic SDH enzyme action shown in Figure 1:
# [[SDHA]] converts [[succinate]] to [[fumarate]] as part of the [[Citric Acid Cycle]]. This reaction also converts [[flavin adenine dinucleotide|FAD]] to [[FADH2|FADH<sub>2</sub>]].
# Electrons from the FADH<sub>2</sub> are transferred to the SDHB subunit [[Iron-sulfur protein|iron clusters]] [2Fe-2S],[4Fe-4S],[3Fe-4S].  
# Finally the electrons are transferred to the [[Ubiquinone]] (Q) pool via the [[succinate dehydrogenase complex subunit C|SDHC]]/[[SDHD]] subunits. This function is part of the [[Respiratory chain]].


==Function of the SDHB protein==
Initially, [[SDHA]] oxidizes [[succinate]] via [[deprotonation]] at the FAD binding site, forming FADH<sub>2</sub> and leaving [[fumarate]], loosely bound to the active site, free to exit the protein. Electrons from FADH<sub>2</sub> are transferred to the SDHB subunit [[Iron-sulfur protein|iron clusters]] [2Fe-2S],[4Fe-4S],[3Fe-4S] and tunnel along the [Fe-S] relay until they reach the [3Fe-4S] [[iron sulfur cluster]]. The electrons are then transferred to an awaiting [[ubiquinone]] molecule at the Q pool active site in the [[SDHC (gene)|SDHC]]/[[SDHD]] dimer. The O1 [[carbonyl]] oxygen of ubiquinone is oriented at the active site (image 4) by [[hydrogen bond]] interactions with Tyr83 of [[SDHD]]. The presence of electrons in the [3Fe-4S] iron sulphur cluster induces the movement of ubiquinone into a second orientation. This facilitates a second hydrogen bond interaction between the O4 carbonyl group of ubiquinone and Ser27 of [[SDHC (gene)|SDHC]]. Following the first single electron reduction step, a [[semiquinone]] radical species is formed. The second electron arrives from the [3Fe-4S] cluster to provide full reduction of the ubiquinone to [[ubiquinol]].<ref>{{cite journal|last1=Horsefield|first1=R|last2=Yankovskaya|first2=V|last3=Sexton|first3=G|last4=Whittingham|first4=W|last5=Shiomi|first5=K|last6=Omura|first6=S|last7=Byrne|first7=B|last8=Cecchini|first8=G|last9=Iwata|first9=S|title=Structural and computational analysis of the quinone-binding site of complex II (succinate-ubiquinone oxidoreductase): a mechanism of electron transfer and proton conduction during ubiquinone reduction.|journal=The Journal of Biological Chemistry|date=17 March 2006|volume=281|issue=11|pages=7309–16|pmid=16407191|doi=10.1074/jbc.m508173200}}</ref>


[[Image:SDHBfunction.svg|thumb|left|400px|Figure 1: Function of the SDHB protein. Electrons are transferred from the Citric Acid Cycle to the Respiratory Chain. Electron path is shown by red arrows.]]
== Clinical significance ==


The SDH complex is located on the inner membrane of the [[mitochondria]] and participates in both the [[Citric Acid Cycle]] and [[Respiratory chain]].
[[Germline]] mutations in the gene can cause familial [[paraganglioma]] (in old nomenclature, Paraganglioma Type PGL4). The same condition is often called familial [[pheochromocytoma]]. Less frequently, [[renal cell carcinoma]] can be caused by  this mutation.


SDHB acts as an intermediate in the basic SDH enzyme action:
Paragangliomas  related to SDHB mutations have a high rate of malignancy. When malignant, treatment is currently the same as for any malignant paraganglioma/pheochromocytoma.
# [[SDHA]] converts [[succinate]] to [[fumarate]] as part of the [[Citric Acid Cycle]]. This reaction also converts [[FAD]] to [[Flavin|FADH<sub>2</sub>]].
# Electrons from the FADH<sub>2</sub> are transferred to the SDHB subunit iron clusters [2Fe-2S],[4Fe-4S],[3Fe-4S].
# Finally the electrons are transferred to the [[Ubiquinone]] (Q) pool via the [[SDHC]]/[[SDHD]] subunits.This function is part of the [[Respiratory chain]].


==Gene that codes for SDHB==
=== Cancer ===
The gene that codes for the SDHB protein is nuclear, not mitchondrial DNA. However,  the protein is located in the inner membrane of the [[mitochondria]]. The location of the gene in humans is on the [[Chromosome 1 (human)|first chromosome]] at p36.1-p35. The [[gene]] is coded in 1123 base pairs, partitioned in 8 [[exon]]s.
The expressed protein has 281 amino acids.
 
==Role in Disease==
[[Germline]] mutations in the gene can cause familial [[paraganglioma]] (in old nomenclature, Paraganglioma Type PGL4). The same condition is often called familial [[pheochromocytoma]].
 
Tumours related to SDHB mutations have a high rate of malignancy. When malignant, treatment is currently the same as for any malignant paraganglioma/pheochromocytoma.
 
===Tumour and Disease Characteristics===


Paragangliomas caused by SDHB mutations have several distinguishing characteristics:
Paragangliomas caused by SDHB mutations have several distinguishing characteristics:


# Malignancy is common, ranging from 38%-83%<ref name="Neumann">Neumann, Hartmut P.H. et al. 2004. Distinct Clinical Features of Paraganglioma Syndromes Associated With SDHB and SDHD Gene Mutations.''Journal of the American Medical Association''. Vol. 292 No. 8. pg. 943- 951.</ref><ref name="Brouwers">Brouwers, Frederieke M. et al. 2006. High Frequency of SDHB Germline Mutations in Patients with Maligant Chatecholamine-Producing Paragangliomas: Implications for Genetic Testing .''J Clin Endocrin Metab.''.</ref> in carriers with disease. In contrast,  tumors caused by [[SDHD]] mutations are almost always benign. Sporadic paragangliomas are malignant in less than 10% of cases.   
# Malignancy is common, ranging from 38%-83%<ref name="Neumann">{{cite journal |vauthors=Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C | title = Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations | journal = JAMA | volume = 292 | issue = 8 | pages = 943–51 |date=August 2004 | pmid = 15328326 | doi = 10.1001/jama.292.8.943 | url = | issn = }}</ref><ref name="Brouwers">{{cite journal |vauthors=Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K | title = High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing | journal = J. Clin. Endocrinol. Metab. | volume = 91 | issue = 11 | pages = 4505–9 |date=November 2006 | pmid = 16912137 | doi = 10.1210/jc.2006-0423 | url = | issn = }}</ref> in carriers with disease. In contrast,  tumors caused by [[SDHD]] mutations are almost always benign. Sporadic paragangliomas are malignant in less than 10% of cases.   
# Malignant paragangliomas caused by SDHB are usually (perhaps 92%<ref name="Brouwers"/>) extra-adrenal. Sporadic pheochromocytomas/paragangliomas are extra-adrenal in less than 10% of cases.   
# Malignant paragangliomas caused by SDHB are usually (perhaps 92%<ref name="Brouwers"/>) extra-adrenal. Sporadic pheochromocytomas/paragangliomas are extra-adrenal in less than 10% of cases.   
# The [[penetrance]] of the gene is often reported as 77% by age 50<ref name="Neumann"/> (i.e. 77% of carriers will have at least one tumour by the age of 50). This is likely an overestimate. Currently (2007), families with silent SDHB mutations are being screened<ref name="NIH">Conference: National Insitute of Health (U.S.A.), "SDHB-related Pheochromocytoma: Recent Discoveries & Current Diagnostic and Therapeutic Approaches", September 29, 2006</ref> to determine the frequency of silent carriers.  
# The [[penetrance]] of the gene is often reported as 77% by age 50<ref name="Neumann"/> (i.e. 77% of carriers will have at least one tumour by the age of 50). This is likely an overestimate. Currently (2011), families with silent SDHB mutations are being screened<ref name="NIH">Conference: National Institute of Health (U.S.A.), "SDHB-related Pheochromocytoma: Recent Discoveries & Current Diagnostic and Therapeutic Approaches", September 29, 2006</ref> to determine the frequency of silent carriers.  
# The average age of onset is approximately the same for SDHB vs non-SDHB related disease (approximately 36 years).  
# The average age of onset is approximately the same for SDHB vs non-SDHB related disease (approximately 36 years).


Mutations causing disease have been seen in [[exon]]s 1 through 7, but not 8. As with  the [[SDHC]] and [[SDHD]] genes, SDHB is a [[tumor suppressor gene]]. Note the [[SDHA]] gene is not a tumor suppressor gene.  
Mutations causing disease have been seen in [[exon]]s 1 through 7, but not 8. As with  the SDHC and [[SDHD]] genes, SDHB is a [[tumor suppressor gene]]. Note the [[SDHA]] gene is not a tumor suppressor gene.


Tumorigenesis follows the Knudson [[Knudson hypothesis|"two hit"]] hypothesis, and so tumour suppressor inactivation usually (but not always) leads to loss of [[Zygosity|heterozygosity]] in tumour cells.  
Tumor formation generally follows the Knudson [[Knudson hypothesis|"two hit"]] hypothesis. The first copy of the gene is mutated in all cells, however the second copy functions normally. When the second copy mutates in a certain cell due to a random event, [[Loss of heterozygosity|Loss of Heterozygosity (LOH)]] occurs and the SDHB protein is no longer produced. Tumor formation then becomes possible.


===Disease pathways===
Given the fundamental nature of the SDH protein in all cellular function, it is not currently understood why only paraganglionic cells are affected. However, the sensitivity of these cells to oxygen levels may play a role.


The precise pathway leading from SDHB mutation to tumorigenesis is not determined; there are several proposed mechanisms<ref name="Gottlieb">Gottlieb, Eyal; Tomlinson, Ian P.M. 2005. Mitochondrial Tumor Suppressors: A Genetic and Biochemical Update.''Nat. Rev. Cancer''. 5(11) pg. 857-866.</ref>.
=== Disease pathways ===
 
The precise pathway leading from SDHB mutation to tumorigenesis is not determined; there are several proposed mechanisms.<ref name="Gottlieb">{{cite journal |vauthors=Gottlieb E, Tomlinson IP | title = Mitochondrial tumour suppressors: a genetic and biochemical update | journal = Nat. Rev. Cancer | volume = 5 | issue = 11 | pages = 857–66 |date=November 2005 | pmid = 16327764 | doi = 10.1038/nrc1737 | url = | issn = }}</ref>
    
    
====Pathway 1: Generation of Reactive Oxygen Species====
==== Generation of reactive oxygen species====


[[Image:SDHBpathways.svg|thumb|left|420px|Figure 2:Disease Pathways for SDHB mutations. Electron path during normal function is  shown by solid red arrows. Red dashed arrow shows superoxide generation (Pathway 1). Purple dashed arrow shows diffusion of succinate to block PHD (Pathway 2). Black crosses indicate the non-mutated process is blocked.]]
[[Image:SDHBpathways.svg|thumb|right|300px|'''Figure 2''': Disease Pathways for SDHB mutations. Electron path during normal function is  shown by solid red arrows. Red dashed arrow shows superoxide generation (Pathway 1). Purple dashed arrow shows diffusion of succinate to block PHD (Pathway 2). Black crosses indicate the non-mutated process is blocked.]]


When succinate-ubiquinone activity is inhibited, electrons that would normally transfer through the SDHB subunit to the Ubiquinone pool are instead transferred to O<sub>2</sub> to create Reactive Oxygen Species (ROS) such as [[superoxide]]. The dashed red arrow in Figure 2 shows this. ROS accumulate and stabilize the production of [[Hypoxia inducible factor|HIF1-α]]. HIF1-α combines with HIF1-β to form the stable HIF heterodimeric complex, in turn leading to the induction  of [[apoptosis|antiapoptotic]] genes in the cell nucleus.  
When succinate-ubiquinone activity is inhibited, electrons that would normally transfer through the SDHB subunit to the Ubiquinone pool are instead transferred to O<sub>2</sub> to create Reactive Oxygen Species (ROS) such as [[superoxide]]. The dashed red arrow in Figure 2 shows this. ROS accumulate and stabilize the production of [[Hypoxia inducible factor|HIF1-α]]. HIF1-α combines with HIF1-β to form the stable HIF heterodimeric complex, in turn leading to the induction  of [[apoptosis|antiapoptotic]] genes in the cell nucleus.


====Pathway 2: Succinate accumulation in the cytosol====
==== Succinate accumulation in the cytosol ====


SDH inactivation can block the oxidation of [[succinate]], starting a cascade of reactions:
SDH inactivation can block the oxidation of [[succinate]], starting a cascade of reactions:
# The succinate accumulated in the mitochondrial matrix  diffuses through the inner and outer mitochondrial membranes to the [[cytosol]] (purple dashed arrows in  Figure 2).
# The succinate accumulated in the mitochondrial matrix  diffuses through the inner and outer mitochondrial membranes to the [[cytosol]] (purple dashed arrows in  Figure 2).
# Under normal cellular function,[[Hypoxia inducible factor|HIF1-α]] in the cytosol is quickly [[hydroxylation|hydroxylated]] by [[prolyl hydroxylase]] (PHD), shown with the light blue arrow. This process is blocked by the accumulated succinate.  
# Under normal cellular function, [[Hypoxia inducible factor|HIF1-α]] in the cytosol is quickly [[hydroxylation|hydroxylated]] by [[prolyl hydroxylase]] (PHD), shown with the light blue arrow. This process is blocked by the accumulated succinate.  
# HIF1-α stabilizes and passes to the cell nucleus (orange arrow) where it forms an active HIF complex (along with HIF1-β) that induces the expression of tumor causing genes <ref name="Selak">Selak, M.A. et al. 2005. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase.''Cancer Cell''. Vol.7 pg. 77-85.</ref>.
# HIF1-α stabilizes and passes to the cell nucleus (orange arrow) where it combines with HIF1-β to form an active HIF complex that induces the expression of tumor causing genes.<ref name="Selak">{{cite journal |vauthors=Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E | title = Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase | journal = Cancer Cell | volume = 7 | issue = 1 | pages = 77–85 |date=January 2005 | pmid = 15652751 | doi = 10.1016/j.ccr.2004.11.022 | url = | issn = }}</ref>
 
This pathway raises the possibility of a therapeutic treatment. The build-up of succinate inhibits PHD activity. PHD action normally requires oxygen and [[α-ketoglutarate|alpha-ketoglutarate]] as [[cosubstrate]]s and ferrous iron and [[Vitamin C|ascorbate]] as [[cofactor (biochemistry)|cofactors]]. Succinate competes with α-ketoglutarate in binding to the PHD enzyme. Therefore, increasing α-ketoglutarate levels can offset the effect of succinate accumulation.


This pathway raises the possibility of a therapeutic treatment. The build-up of succinate inhibits PHD activity. PHD action normally requires oxygen and [[α-ketoglutarate|alpha-ketoglutarate]] as [[cosubstrate|cosubstrates]] and ferrous iron and [[Vitamin C|ascorbate]] as [[cofactor (biochemistry)|cofactors]]. Succinate competes with α-ketoglutarate in binding to the PHD enzyme. Therefore, increasing α-ketoglutarate levels can offset the effect of succinate accumulation.  
Normal α-ketoglutarate does not permeate cell walls efficiently, and it is necessary to create a cell permeating derivative (e.g. α-ketoglutarate esters). In-vitro trials show this supplementation approach can reduce HIF1-α levels, and may result in a therapeutic approach to tumours resulting from SDH deficiency.<ref name="MacKenzie">{{cite journal |vauthors=MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E | title = Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells | journal = Mol. Cell. Biol. | volume = 27 | issue = 9 | pages = 3282–9 |date=May 2007 | pmid = 17325041 | pmc = 1899954 | doi = 10.1128/MCB.01927-06 | url = | issn = }}</ref>


Normal α-ketoglutarate does not permeate cell walls efficiently, and it is necessary to create a cell permeating derivative (e.g. α-ketoglutarate esters). In-vitro trials show this supplementation approach can reduce HIF1-α levels, and may result in a therapeutic approach to tumours resulting from SDH deficiency<ref name="MacKenzie">MacKenzie, Elaine D. et al. May 2007. Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells.''Molecular and Cellular Biology''. Vol.27,No.9 pg. 3282-3289.</ref>.
====  Impaired developmental apoptosis ====


====Pathway 3: Impaired Developmental Apoptosis====
Paraganglionic tissue is derived from the [[neural crest]] cells present in an [[embryo]]. Abdominal extra-adrenal paraganglionic cells secrete catecholamines that play an important role in fetal development. After birth these cells usually die, a process that is triggered by a decline in [[nerve growth factor]] (NGF)which initiates [[apoptosis]] (cell death).


Paraganglionic tissue is derived from the [[neural crest]] cells present in an [[embryo]]. Abdominal extra-adrenal paraganglionic cells secrete catecholamines that play an important role in fetal development. After birth these cells usually die, a process that is triggered by a decline in [[nerve growth factor]] (NGF)which initiates [[apoptosis]] (cell death).  
This cell death process is mediated by an enzyme called prolyl hydroxylase EglN3. Succinate accumulation caused by SDH inactivation inhibits the prolyl hydroxylase EglN3.<ref name="Lee">{{cite journal |vauthors=Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Schlisio S | title = Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer | journal = Cancer Cell | volume = 8 | issue = 2 | pages = 155–67 |date=August 2005 | pmid = 16098468 | doi = 10.1016/j.ccr.2005.06.015 | url = | issn = }}</ref> The net result is that paranglionic tissue that would normally die after birth remains, and this tissue may be able to trigger paraganglioma/pheochromocytoma later.


This cell death process is mediated by an enzyme called prolyl hydroxylase EglN3. Succinate accumulation caused by SDH inactivation inhibits the prolyl hydroxylase EglN3<ref name="Lee">Lee S., Nakamura E., et al. August 2005. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.''Cancer Cell''. Vol.8,pg. 155-167.</ref>..
==== Glycolysis upregulation ====
Inhibition of the Citric Acid Cycle forces the cell to create [[adenosine triphosphate|ATP]] glycolytically in order to generate its required energy. The induced glycolytic enzymes could potentially block cell apoptosis.


The net result is that paranglionic tissue that would normally die after birth remains, and this tissue may be able to trigger paraganglioma/pheochromocytoma later.  
===RNA editing===
The mRNA transcripts of the SDHB gene in human are edited through an unknown mechanism at ORF nucleotide position 136 causing the conversion of C to U and thus generating a stop codon resulting in the translation of the edited transcripts to a truncated SDHB protein with an R46X amino acid change. This editing has been shown in [[monocytes]] and some human lymphoid cell-lines,<ref name="Baysal_2013">{{cite journal | author = Baysal BE | title = A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia | journal = PLoS ONE | volume = 2 | issue = 5 | pages = e436 | year = 2007 | pmid = 17487275 | pmc = 1855983 | doi = 10.1371/journal.pone.0000436 }} {{open access}}</ref> and is enhanced by [[Hypoxia (medical)|hypoxia]].<ref name="Baysal_2007">{{cite journal |vauthors=Baysal BE, De Jong K, Liu B, Wang J, Patnaik SK, Wallace PK, Taggart RT | title = Hypoxia-inducible C-to-U coding RNA editing downregulates SDHB in monocytes | journal = PeerJ | volume = 1 | issue = | pages = e152 | year = 2013 | pmid = 24058882 | pmc = 3775634 | doi = 10.7717/peerj.152 }}</ref>


====Pathway 4: Glycolysis upregulation====
== Interactive pathway map ==
Inhibition of the Citric Acid Cycle forces the cell to generate [[adenosine triphosphate|ATP]] glycolytically in order to generate its required energy. The induced glycolytic enzymes could potentially block cell apoptosis.
{{TCACycle_WP78|highlight=SDHB}}


==External links==
== References ==
{{reflist|2}}


* [http://chromium.liacs.nl/lovd_sdh/index.php?select_db=SDHB Database of identified mutations.]
== Further reading ==
* [http://p078.ezboard.com/SDHB-Mutations/fpheochromocytomasupportboardfrm20 Message Board for SDHB Mutations]
{{refbegin | 2}}
*{{cite journal  |vauthors=Milosevic D, Lundquist P, Cradic K, etal |title=Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. |journal=Clin. Biochem. |volume=43 |issue= 7-8 |pages= 700–4 |year= 2010 |pmid= 20153743 |doi= 10.1016/j.clinbiochem.2010.01.016 |pmc=3419008}}
*{{cite journal  |vauthors=Alrashdi I, Bano G, Maher ER, Hodgson SV |title=Carney triad versus Carney Stratakis syndrome: two cases which illustrate the difficulty in distinguishing between these conditions in individual patients. |journal=Fam. Cancer |volume=9 |issue= 3 |pages= 443–7 |year= 2010 |pmid= 20119652 |doi= 10.1007/s10689-010-9323-z }}
*{{cite journal  |vauthors=Okada Y, Kamatani Y, Takahashi A, etal |title=A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci. |journal=Hum. Mol. Genet. |volume=19 |issue= 11 |pages= 2303–12 |year= 2010 |pmid= 20189936 |doi= 10.1093/hmg/ddq091 }}
*{{cite journal  |author=Bayley JP |title=Are these compound heterozygous mutations of SDHB really mutations? |journal=Pediatr Blood Cancer |volume=55 |issue= 1 |pages= 211; author reply 212 |year= 2010 |pmid= 20213850 |doi= 10.1002/pbc.22455 }}
*{{cite journal  |vauthors=Rose JE, Behm FM, Drgon T, etal |title=Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. |journal=Mol. Med. |volume=16 |issue= 7-8 |pages= 247–53 |year=  2010|pmid= 20379614  |pmc=2896464 |doi= 10.2119/molmed.2009.00159 }}
*{{cite journal  |vauthors=Gill AJ, Benn DE, Chou A, etal |title=Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. |journal=Hum. Pathol. |volume=41 |issue= 6 |pages= 805–14 |year= 2010 |pmid= 20236688 |doi= 10.1016/j.humpath.2009.12.005 }}
*{{cite journal  |vauthors=Martin TP, Irving RM, Maher ER |title=The genetics of paragangliomas: a review. |journal=Clin Otolaryngol |volume=32 |issue= 1 |pages= 7–11 |year= 2007 |pmid= 17298303 |doi= 10.1111/j.1365-2273.2007.01378.x }}
*{{cite journal  |vauthors=Eng C, Kiuru M, Fernandez MJ, Aaltonen LA |title=A role for mitochondrial enzymes in inherited neoplasia and beyond. |journal=Nat. Rev. Cancer |volume=3 |issue= 3 |pages= 193–202 |year= 2003 |pmid= 12612654 |doi= 10.1038/nrc1013 }}
*{{cite journal  |vauthors=Lee J, Wang J, Torbenson M, etal |title=Loss of SDHB and NF1 genes in a malignant phyllodes tumor of the breast as detected by oligo-array comparative genomic hybridization. |journal=Cancer Genet. Cytogenet. |volume=196 |issue= 2 |pages= 179–83 |year= 2010 |pmid= 20082856 |doi= 10.1016/j.cancergencyto.2009.09.005 }}
*{{cite journal  |vauthors=Hermsen MA, Sevilla MA, Llorente JL, etal |title=Relevance of germline mutation screening in both familial and sporadic head and neck paraganglioma for early diagnosis and clinical management. |journal=Cell. Oncol. |volume=32 |issue= 4 |pages= 275–83 |year= 2010 |pmid= 20208144 |doi= 10.3233/CLO-2009-0498 }}
*{{cite journal  |author1=Musil Z |author2=Puchmajerová A |author3=Krepelová A |title=Paraganglioma in a 13-year-old girl: a novel SDHB gene mutation in the family? |journal=Cancer Genet. Cytogenet. |volume=197 |issue= 2 |pages= 189–92 |year= 2010 |pmid= 20193854 |doi= 10.1016/j.cancergencyto.2009.11.010 |display-authors=etal}}
*{{cite journal  |vauthors=Shimada M, Miyagawa T, Kawashima M, etal |title=An approach based on a genome-wide association study reveals candidate loci for narcolepsy. |journal=Hum. Genet. |volume=128 |issue= 4 |pages= 433–41 |year= 2010 |pmid= 20677014 |doi= 10.1007/s00439-010-0862-z }}
*{{cite journal  |author1=Brière JJ |author2=Favier J |author3=El Ghouzzi V |title=Succinate dehydrogenase deficiency in human. |journal=Cell. Mol. Life Sci. |volume=62 |issue= 19-20 |pages= 2317–24 |year= 2005 |pmid= 16143825 |doi= 10.1007/s00018-005-5237-6 |display-authors=etal}}
*{{cite journal  |vauthors=Schimke RN, Collins DL, Stolle CA |title=Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery. |journal=Am. J. Med. Genet. A |volume=152A |issue= 6 |pages= 1531–5 |year= 2010 |pmid= 20503330 |doi= 10.1002/ajmg.a.33384 }}
*{{cite journal  |vauthors=Gill AJ, Chou A, Vilain R, etal |title=Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. |journal=Am. J. Surg. Pathol. |volume=34 |issue= 5 |pages= 636–44 |year= 2010 |pmid= 20305538 |doi= 10.1097/PAS.0b013e3181d6150d }}
*{{cite journal  |vauthors=Hendrickson SL, Lautenberger JA, Chinn LW, etal |title=Genetic variants in nuclear-encoded mitochondrial genes influence AIDS progression. |journal=PLoS ONE |volume=5 |issue= 9 |pages= e12862 |year= 2010 |pmid= 20877624  |pmc=2943476 |doi= 10.1371/journal.pone.0012862 }} {{open access}}
*{{cite journal  |vauthors=Cerecer-Gil NY, Figuera LE, Llamas FJ, etal |title=Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma. |journal=Clin. Cancer Res. |volume=16 |issue= 16 |pages= 4148–54 |year= 2010 |pmid= 20592014 |doi= 10.1158/1078-0432.CCR-10-0637 }}
*{{cite journal  |vauthors=Krawczyk A, Hasse-Lazar K, Pawlaczek A, etal |title=Germinal mutations of RET, SDHB, SDHD, and VHL genes in patients with apparently sporadic pheochromocytomas and paragangliomas. |journal=Endokrynol Pol |volume=61 |issue= 1 |pages= 43–8 |year=  2010|pmid= 20205103 |doi=  }}
*{{cite journal  |vauthors=Hes FJ, Weiss MM, Woortman SA, etal |title=Low penetrance of a SDHB mutation in a large Dutch paraganglioma family. |journal=BMC Med. Genet. |volume=11 |issue=  |pages= 92 |year= 2010 |pmid= 20540712  |pmc=2891715 |doi= 10.1186/1471-2350-11-92 }} {{open access}}
*{{cite journal  |vauthors=Bailey SD, Xie C, Do R, etal |title=Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. |journal=Diabetes Care |volume=33 |issue= 10 |pages= 2250–3 |year= 2010 |pmid= 20628086  |pmc=2945168 |doi= 10.2337/dc10-0452 }}
*{{cite journal  |author=Baysal BE |title=A Recurrent Stop-Codon Mutation in Succinate Dehydrogenase Subunit B Gene in Normal Peripheral Blood and Childhood T-Cell Acute Leukemia. |journal=PLOS ONE |volume=2 |issue= 5 |pages= e436 |year= 2007 |pmid= 17487275  |pmc=1855983 |doi= 10.1371/journal.pone.0000436 }} {{open access}}
*{{cite journal  |vauthors=Baysal BE, Jong KD, Liu B, etal |title=Hypoxia-inducible C-to-U coding RNA editing downregulates SDHB in monocytes. |journal=PeerJ |volume=1 |pages= e152 |year= 2013 |pmid= 24058882 |doi= 10.7717/peerj.152 |pmc=3775634}}
{{refend}}


==References==
== External links ==
<div class="references-small">
* [http://chromium.liacs.nl/lovd_sdh/index.php?select_db=SDHB Database of identified SDHB mutations.]
<references/></div>


{{PDB Gallery|geneid=6390}}
{{Citric acid cycle enzymes}}
{{Citric acid cycle enzymes}}
{{Tumor suppressor genes}}
{{CH-CH oxidoreductases}}
{{Enzymes}}
{{Portal bar|Molecular and Cellular Biology|border=no}}


[[Category:Genes]]
[[Category:EC 1.3.5]]
[[Category:Human genes]]
[[Category:Tumor suppressor genes]]
[[Category:Tumor suppressor genes]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Revision as of 12:38, 30 October 2017

VALUE_ERROR (nil)
Identifiers
Aliases
External IDsGeneCards: [1]
Orthologs
SpeciesHumanMouse
Entrez

n/a

n/a

Ensembl

n/a

n/a

UniProt

n/a

n/a

RefSeq (mRNA)

n/a

n/a

RefSeq (protein)

n/a

n/a

Location (UCSC)n/an/a
PubMed searchn/an/a
Wikidata
View/Edit Human

Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial (SDHB) also known as iron-sulfur subunit of complex II (Ip) is a protein that in humans is encoded by the SDHB gene.[1][2][3]

The succinate dehydrogenase (also called SDH or Complex II) protein complex catalyzes the oxidation of succinate (succinate + ubiquinone => fumarate + ubiquinol). SDHB is one of four protein subunits forming succinate dehydrogenase, the other three being SDHA, SDHC and SDHD. The SDHB subunit is connected to the SDHA subunit on the hydrophilic, catalytic end of the SDH complex. It is also connected to the SDHC/SDHD subunits on the hydrophobic end of the complex anchored in the mitochondrial membrane. The subunit is an iron-sulfur protein with three iron-sulfur clusters. It weighs 30 kDa.

Structure

The gene that codes for the SDHB protein is nuclear, not mitchondrial DNA. However, the expressed protein is located in the inner membrane of the mitochondria. The location of the gene in humans is on the first chromosome at locus p36.1-p35. The gene is coded in 1,162 base pairs, partitioned in 8 exons.[1] The expressed protein weighs 18.6 kDa and is composed of 180 amino acids.[4][5] SDHB contains the iron-sulphur clusters necessary for tunneling electrons through the complex. It is located between SDHA and the two transmembrane subunits SDHC and SDHD.[6]

Function

File:SDHBfunction.svg
Figure 1: Function of the SDHB protein. Electrons are transferred from the Citric Acid Cycle to the Respiratory Chain. Electron path is shown by red arrows.

The SDH complex is located on the inner membrane of the mitochondria and participates in both the Citric Acid Cycle and Respiratory chain. SDHB acts as an intermediate in the basic SDH enzyme action shown in Figure 1:

  1. SDHA converts succinate to fumarate as part of the Citric Acid Cycle. This reaction also converts FAD to FADH2.
  2. Electrons from the FADH2 are transferred to the SDHB subunit iron clusters [2Fe-2S],[4Fe-4S],[3Fe-4S].
  3. Finally the electrons are transferred to the Ubiquinone (Q) pool via the SDHC/SDHD subunits. This function is part of the Respiratory chain.

Initially, SDHA oxidizes succinate via deprotonation at the FAD binding site, forming FADH2 and leaving fumarate, loosely bound to the active site, free to exit the protein. Electrons from FADH2 are transferred to the SDHB subunit iron clusters [2Fe-2S],[4Fe-4S],[3Fe-4S] and tunnel along the [Fe-S] relay until they reach the [3Fe-4S] iron sulfur cluster. The electrons are then transferred to an awaiting ubiquinone molecule at the Q pool active site in the SDHC/SDHD dimer. The O1 carbonyl oxygen of ubiquinone is oriented at the active site (image 4) by hydrogen bond interactions with Tyr83 of SDHD. The presence of electrons in the [3Fe-4S] iron sulphur cluster induces the movement of ubiquinone into a second orientation. This facilitates a second hydrogen bond interaction between the O4 carbonyl group of ubiquinone and Ser27 of SDHC. Following the first single electron reduction step, a semiquinone radical species is formed. The second electron arrives from the [3Fe-4S] cluster to provide full reduction of the ubiquinone to ubiquinol.[7]

Clinical significance

Germline mutations in the gene can cause familial paraganglioma (in old nomenclature, Paraganglioma Type PGL4). The same condition is often called familial pheochromocytoma. Less frequently, renal cell carcinoma can be caused by this mutation.

Paragangliomas related to SDHB mutations have a high rate of malignancy. When malignant, treatment is currently the same as for any malignant paraganglioma/pheochromocytoma.

Cancer

Paragangliomas caused by SDHB mutations have several distinguishing characteristics:

  1. Malignancy is common, ranging from 38%-83%[8][9] in carriers with disease. In contrast, tumors caused by SDHD mutations are almost always benign. Sporadic paragangliomas are malignant in less than 10% of cases.
  2. Malignant paragangliomas caused by SDHB are usually (perhaps 92%[9]) extra-adrenal. Sporadic pheochromocytomas/paragangliomas are extra-adrenal in less than 10% of cases.
  3. The penetrance of the gene is often reported as 77% by age 50[8] (i.e. 77% of carriers will have at least one tumour by the age of 50). This is likely an overestimate. Currently (2011), families with silent SDHB mutations are being screened[10] to determine the frequency of silent carriers.
  4. The average age of onset is approximately the same for SDHB vs non-SDHB related disease (approximately 36 years).

Mutations causing disease have been seen in exons 1 through 7, but not 8. As with the SDHC and SDHD genes, SDHB is a tumor suppressor gene. Note the SDHA gene is not a tumor suppressor gene.

Tumor formation generally follows the Knudson "two hit" hypothesis. The first copy of the gene is mutated in all cells, however the second copy functions normally. When the second copy mutates in a certain cell due to a random event, Loss of Heterozygosity (LOH) occurs and the SDHB protein is no longer produced. Tumor formation then becomes possible.

Given the fundamental nature of the SDH protein in all cellular function, it is not currently understood why only paraganglionic cells are affected. However, the sensitivity of these cells to oxygen levels may play a role.

Disease pathways

The precise pathway leading from SDHB mutation to tumorigenesis is not determined; there are several proposed mechanisms.[11]

Generation of reactive oxygen species

File:SDHBpathways.svg
Figure 2: Disease Pathways for SDHB mutations. Electron path during normal function is shown by solid red arrows. Red dashed arrow shows superoxide generation (Pathway 1). Purple dashed arrow shows diffusion of succinate to block PHD (Pathway 2). Black crosses indicate the non-mutated process is blocked.

When succinate-ubiquinone activity is inhibited, electrons that would normally transfer through the SDHB subunit to the Ubiquinone pool are instead transferred to O2 to create Reactive Oxygen Species (ROS) such as superoxide. The dashed red arrow in Figure 2 shows this. ROS accumulate and stabilize the production of HIF1-α. HIF1-α combines with HIF1-β to form the stable HIF heterodimeric complex, in turn leading to the induction of antiapoptotic genes in the cell nucleus.

Succinate accumulation in the cytosol

SDH inactivation can block the oxidation of succinate, starting a cascade of reactions:

  1. The succinate accumulated in the mitochondrial matrix diffuses through the inner and outer mitochondrial membranes to the cytosol (purple dashed arrows in Figure 2).
  2. Under normal cellular function, HIF1-α in the cytosol is quickly hydroxylated by prolyl hydroxylase (PHD), shown with the light blue arrow. This process is blocked by the accumulated succinate.
  3. HIF1-α stabilizes and passes to the cell nucleus (orange arrow) where it combines with HIF1-β to form an active HIF complex that induces the expression of tumor causing genes.[12]

This pathway raises the possibility of a therapeutic treatment. The build-up of succinate inhibits PHD activity. PHD action normally requires oxygen and alpha-ketoglutarate as cosubstrates and ferrous iron and ascorbate as cofactors. Succinate competes with α-ketoglutarate in binding to the PHD enzyme. Therefore, increasing α-ketoglutarate levels can offset the effect of succinate accumulation.

Normal α-ketoglutarate does not permeate cell walls efficiently, and it is necessary to create a cell permeating derivative (e.g. α-ketoglutarate esters). In-vitro trials show this supplementation approach can reduce HIF1-α levels, and may result in a therapeutic approach to tumours resulting from SDH deficiency.[13]

Impaired developmental apoptosis

Paraganglionic tissue is derived from the neural crest cells present in an embryo. Abdominal extra-adrenal paraganglionic cells secrete catecholamines that play an important role in fetal development. After birth these cells usually die, a process that is triggered by a decline in nerve growth factor (NGF)which initiates apoptosis (cell death).

This cell death process is mediated by an enzyme called prolyl hydroxylase EglN3. Succinate accumulation caused by SDH inactivation inhibits the prolyl hydroxylase EglN3.[14] The net result is that paranglionic tissue that would normally die after birth remains, and this tissue may be able to trigger paraganglioma/pheochromocytoma later.

Glycolysis upregulation

Inhibition of the Citric Acid Cycle forces the cell to create ATP glycolytically in order to generate its required energy. The induced glycolytic enzymes could potentially block cell apoptosis.

RNA editing

The mRNA transcripts of the SDHB gene in human are edited through an unknown mechanism at ORF nucleotide position 136 causing the conversion of C to U and thus generating a stop codon resulting in the translation of the edited transcripts to a truncated SDHB protein with an R46X amino acid change. This editing has been shown in monocytes and some human lymphoid cell-lines,[15] and is enhanced by hypoxia.[16]

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. [§ 1]

[[File:
<imagemap> Image:TCACycle WP78.png
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
<imagemap> Image:TCACycle WP78.png
|{{{bSize}}}px|alt=TCA Cycle edit]]
TCA Cycle edit
  1. ↑ The interactive pathway map can be edited at WikiPathways: "TCACycle_WP78".

References

  1. ↑ 1.0 1.1 "Entrez Gene: succinate dehydrogenase complex".
  2. ↑ Kita K, Oya H, Gennis RB, Ackrell BA, Kasahara M (January 1990). "Human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of iron sulfur (Ip) subunit of liver mitochondria". Biochem. Biophys. Res. Commun. 166 (1): 101–8. doi:10.1016/0006-291X(90)91916-G. PMID 2302193.
  3. ↑ Au HC, Ream-Robinson D, Bellew LA, Broomfield PL, Saghbini M, Scheffler IE (July 1995). "Structural organization of the gene encoding the human iron-sulfur subunit of succinate dehydrogenase". Gene. 159 (2): 249–53. doi:10.1016/0378-1119(95)00162-Y. PMID 7622059.
  4. ↑ Zong NC, Li H, Li H, Lam MP, Jimenez RC, Kim CS, Deng N, Kim AK, Choi JH, Zelaya I, Liem D, Meyer D, Odeberg J, Fang C, Lu HJ, Xu T, Weiss J, Duan H, Uhlen M, Yates JR, Apweiler R, Ge J, Hermjakob H, Ping P (Oct 2013). "Integration of cardiac proteome biology and medicine by a specialized knowledgebase". Circulation Research. 113 (9): 1043–53. doi:10.1161/CIRCRESAHA.113.301151. PMC 4076475. PMID 23965338.
  5. ↑ "SDHB - Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial". Cardiac Organellar Protein Atlas Knowledgebase (COPaKB).
  6. ↑ Sun, F; Huo, X; Zhai, Y; Wang, A; Xu, J; Su, D; Bartlam, M; Rao, Z (1 July 2005). "Crystal structure of mitochondrial respiratory membrane protein complex II". Cell. 121 (7): 1043–57. doi:10.1016/j.cell.2005.05.025. PMID 15989954.
  7. ↑ Horsefield, R; Yankovskaya, V; Sexton, G; Whittingham, W; Shiomi, K; Omura, S; Byrne, B; Cecchini, G; Iwata, S (17 March 2006). "Structural and computational analysis of the quinone-binding site of complex II (succinate-ubiquinone oxidoreductase): a mechanism of electron transfer and proton conduction during ubiquinone reduction". The Journal of Biological Chemistry. 281 (11): 7309–16. doi:10.1074/jbc.m508173200. PMID 16407191.
  8. ↑ 8.0 8.1 Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C (August 2004). "Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations". JAMA. 292 (8): 943–51. doi:10.1001/jama.292.8.943. PMID 15328326.
  9. ↑ 9.0 9.1 Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K (November 2006). "High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing". J. Clin. Endocrinol. Metab. 91 (11): 4505–9. doi:10.1210/jc.2006-0423. PMID 16912137.
  10. ↑ Conference: National Institute of Health (U.S.A.), "SDHB-related Pheochromocytoma: Recent Discoveries & Current Diagnostic and Therapeutic Approaches", September 29, 2006
  11. ↑ Gottlieb E, Tomlinson IP (November 2005). "Mitochondrial tumour suppressors: a genetic and biochemical update". Nat. Rev. Cancer. 5 (11): 857–66. doi:10.1038/nrc1737. PMID 16327764.
  12. ↑ Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E (January 2005). "Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase". Cancer Cell. 7 (1): 77–85. doi:10.1016/j.ccr.2004.11.022. PMID 15652751.
  13. ↑ MacKenzie ED, Selak MA, Tennant DA, Payne LJ, Crosby S, Frederiksen CM, Watson DG, Gottlieb E (May 2007). "Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells". Mol. Cell. Biol. 27 (9): 3282–9. doi:10.1128/MCB.01927-06. PMC 1899954. PMID 17325041.
  14. ↑ Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Schlisio S (August 2005). "Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer". Cancer Cell. 8 (2): 155–67. doi:10.1016/j.ccr.2005.06.015. PMID 16098468.
  15. ↑ Baysal BE (2007). "A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia". PLoS ONE. 2 (5): e436. doi:10.1371/journal.pone.0000436. PMC 1855983. PMID 17487275. open access publication – free to read
  16. ↑ Baysal BE, De Jong K, Liu B, Wang J, Patnaik SK, Wallace PK, Taggart RT (2013). "Hypoxia-inducible C-to-U coding RNA editing downregulates SDHB in monocytes". PeerJ. 1: e152. doi:10.7717/peerj.152. PMC 3775634. PMID 24058882.

Further reading

External links

Retrieved from "https://www.wikidoc.org/index.php?title=SDHB&oldid=1410675"